Shares of 5N Plus Inc. (OTCMKTS:FPLSF – Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $28.4880, but opened at $26.2610. 5N Plus shares last traded at $26.24, with a volume of 571 shares traded.
Analyst Ratings Changes
Separately, Scotiabank initiated coverage on 5N Plus in a research report on Monday, June 22nd. They set an “outperform” rating for the company. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy”.
Get Our Latest Research Report on 5N Plus
5N Plus Trading Down 7.9%
5N Plus (OTCMKTS:FPLSF – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. 5N Plus had a net margin of 13.99% and a return on equity of 28.72%. The company had revenue of $117.89 million during the quarter, compared to analyst estimates of $104.04 million.
5N Plus Company Profile
5N Plus Inc is a Canadian specialty chemicals and materials company that develops, manufactures and commercializes high‐purity metals and compounds for advanced technology markets. The company’s product portfolio spans a range of elemental metals—including bismuth, antimony, tellurium, selenium, indium and germanium—along with organometallic precursors, catalysts and radioisotopes. These materials are engineered to meet stringent purity standards (commonly known as “five‐nines” or 99.999% purity) for critical applications in electronics, photovoltaics, catalysts and life sciences.
Founded in 2000 and headquartered in Boucherville, Quebec, 5N Plus has grown from its roots in high‐purity research to a global manufacturing and distribution platform.
See Also
- Five stocks we like better than 5N Plus
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
- The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
Receive News & Ratings for 5N Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 5N Plus and related companies with MarketBeat.com's FREE daily email newsletter.
